• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coron

tetano

Editor, Senior Moderator
J Infect Dis


. 2025 May 20:jiaf246.
doi: 10.1093/infdis/jiaf246. Online ahead of print. Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants

Holly E Baum[SUP] 1 2 [/SUP], Marianna Santopaolo[SUP] 1 [/SUP], Ore Francis[SUP] 1 3 [/SUP], Emily J Milodowski[SUP] 3 [/SUP], Katrina Entwistle[SUP] 3 [/SUP], Elizabeth Oliver[SUP] 1 2 [/SUP], Benjamin Hitchings[SUP] 1 2 [/SUP], Divya Diamond[SUP] 1 [/SUP], Amy C Thomas[SUP] 4 [/SUP], Ruth E Mitchell[SUP] 4 [/SUP], Milla Kibble[SUP] 4 5 6 [/SUP], Kapil Gupta[SUP] 7 [/SUP], Natalie Di Bartolo[SUP] 7 [/SUP], Paul Klenerman[SUP] 8 [/SUP], Anthony Brown[SUP] 9 [/SUP], Begonia Morales-Aza[SUP] 1 2 [/SUP], Jennifer Oliver[SUP] 2 4 [/SUP], Imre Berger[SUP] 7 [/SUP], Ash M Toye[SUP] 7 [/SUP], Adam Finn[SUP] 1 2 4 10 [/SUP], Anu Goenka[SUP] 1 2 4 10 [/SUP], Andrew D Davidson[SUP] 1 [/SUP], Susan Ring[SUP] 4 11 [/SUP], Lynn Molloy[SUP] 4 [/SUP], Melanie Lewcock[SUP] 4 [/SUP], Kate Northstone[SUP] 4 [/SUP], Firona Roth[SUP] 4 [/SUP], Nicholas J Timpson[SUP] 4 11 [/SUP], Linda Wooldridge[SUP] 3 [/SUP], Alice Halliday[SUP] 1 2 [/SUP], Laura Rivino[SUP] 1 [/SUP]



Affiliations
Abstract

Background: Immunological memory to vaccination and viral infection involves the coordinated action of B and T cells; thus, integrated analysis of these 2 components is critical for understanding their respective contributions to protection against breakthrough infections (BIs) after vaccination.
Methods: We investigated cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or vaccination in 300 adult participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). Participants were grouped by those with (cases) and without (controls) a history of SARS-CoV-2 infection. To provide a quantitative correlate for protection against BI in the 8-month period after the study, Youden index thresholds were calculated for all immune measures analyzed.
Results: The magnitude of antibody and T-cell responses following the second vaccine dose was associated with protection against BI in participants with a history of SARS-CoV-2 infection (cases), but not in infection-naive controls. Over 8 months of follow-up, 2 threshold combinations provided the best performance for protection against BI in cases: (i) anti-spike immunoglobulin G (IgG) (≥666.4 binding antibody units [BAU]/mL) combined with anti-nucleocapsid pan-immunoglobulin (pan-Ig) (≥0.1332 BAU/mL) and (ii) spike 1-specific T cells (≥195.6 spot-forming units/106 peripheral blood mononuclear cells) combined with anti-N pan-Ig (≥0.1332 BAU/mL). Both combinations offered 100% specificity for detecting cases without BI, with sensitivities of 83.3% and 72.2%, respectively.
Conclusions: Collectively, these results suggest that hybrid B- and T-cell immunity offers superior protection from BI after coronavirus disease 2019 (COVID-19) vaccination, and this finding has implications for designing next-generation COVID-19 vaccines that are capable of eliciting immunity to a broader repertoire of SARS-CoV-2 proteins.

Keywords: ALSPAC; SARS-CoV-2; breakthrough infection; hybrid immunity; vaccination.

 
Back
Top Bottom